Area of research
Infectious Diseases · Immunology
Research interest
Research interests include Clostridium difficile and Clostridium perfringens research, Immune Response and Inflammation, Inflammatory Bowel Disease, and Escherichia coli research studies.
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.
Altered receptor binding, antibody evasion and retention of T cell recognition by the SARS-CoV-2 XBB.1.5 spike protein.
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Dysregulated Immunity to Clostridioides difficile in IBD Patients Without a History of Recognized Infection.
Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study.
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Quantitative analysis of the impact of infectious disease physicians on patients in the emergency department fast-track parenteral antibiotics program.
T-cell activation-induced marker assays in health and disease.
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent <i>Clostridioides difficile</i> Infection
Flagellin-specific human CAR Tregs for immune regulation in IBD
Clostridioides difficile PCR Tcdb Cycle Threshold predicts toxin EIA positivity but not severity of infection.
How to present work productivity loss results from clinical trials for patients and caregivers? A mixed methods approach.
Evading the Toll booth: How "silent" flagellins may bind yet fail to activate TLR5.
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses
Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses.
An in vitro chronic damage model impairs inflammatory and regenerative responses in human colonoid monolayers.
Inhibition of glycogen synthase kinase-3-beta (GSK3β) blocks nucleocapsid phosphorylation and SARS-CoV-2 replication.
Improving care for patients with <i>Clostridioides difficile</i> infection: A clinical practice and healthcare systems perspective.
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.
A method for expansion and retroviral transduction of mouse regulatory T cells.
Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Enhances Adaptive Immunity to C difficile Toxin B.
Recurrent Clostridioides difficile Infection Is Associated With Impaired T Helper Type 17 Immunity to C difficile Toxin B.
Prevalence, persistence, and genetics of antibody responses to protein toxins and virulence factors
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial
Regenerative Intestinal Stem Cells Induced by Acute and Chronic Injury: The Saving Grace of the Epithelium?